LPL（脂蛋白脂肪酶）是一种关键的代谢酶，主要功能是水解血液中乳糜微粒和极低密度脂蛋白（VLDL）中的甘油三酯，释放游离脂肪酸供组织利用。它在脂肪组织、心肌和骨骼肌等毛细血管内皮细胞表面表达，是脂质代谢的核心调控因子之一。LPL的活性受多种因素调节，包括胰岛素、apoC-II（激活剂）和apoC-III（抑制剂）。该基因属于脂酶基因家族，成员包括肝脂肪酶（LPL）和内皮脂肪酶（LIPG），它们共享水解脂质的功能，但作用底物和组织分布不同。LPL基因突变可导致家族性乳糜微粒血症（I型高脂蛋白血症），表现为严重的高甘油三酯血症、胰腺炎和黄色瘤。功能丧失性突变会完全破坏酶活性，而部分功能突变可能导致轻度表型。LPL过表达会增强脂质清除，可能改善胰岛素敏感性，但过度活化可能导致脂肪异常堆积；反之，表达降低会引发高甘油三酯血症和心血管风险增加。LPL与动脉粥样硬化、肥胖和糖尿病密切相关，其多态性（如S447X）可影响心血管疾病易感性。此外，LPL还参与炎症反应和巨噬细胞脂质代谢，在肿瘤微环境中可能通过调节脂肪酸供应影响癌细胞生长。

LPL编码脂蛋白脂肪酶，其在心脏，肌肉和脂肪组织中表达。 LPL用作同型二聚体，并具有甘油三酯水解酶和配体/桥接因子的受体介导的脂蛋白摄取的双重功能。严重的突变引起的LPL不足导致I型高脂蛋白血症，而在LPL的不太极端的突变都与脂蛋白代谢的许多病症。 [由RefSeq的，2008年7月提供]

Lipoprotein lipase (LPL) is a pivotal metabolic enzyme that serves as the primary catalyst for the hydrolysis of triglycerides within circulating chylomicrons and very-low-density lipoproteins (VLDL), thereby liberating free fatty acids for uptake and utilization by peripheral tissues. Expressed predominantly on the luminal surface of capillary endothelial cells in adipose tissue, the heart, and skeletal muscle, LPL acts as a central regulator of systemic lipid homeostasis. Its enzymatic activity is tightly modulated by a complex interplay of regulatory factors, including insulin, which generally suppresses activity, and apolipoprotein C-II, which acts as an essential cofactor for activation, while apolipoprotein C-III serves as a potent inhibitor. As a member of the lipase gene family, LPL shares structural and functional homology with other lipases such as hepatic lipase and endothelial lipase (LIPG), though these enzymes differ in their specific substrate preferences and tissue distribution profiles. Genetic alterations in the LPL gene have significant clinical implications; loss-of-function mutations can result in familial chylomicronemia syndrome (Type I hyperlipoproteinemia), a severe disorder characterized by extreme hypertriglyceridemia, recurrent pancreatitis, and the development of xanthomas, whereas partial loss-of-function variants may manifest as milder phenotypes. Conversely, while enhanced LPL expression can accelerate lipid clearance and potentially improve insulin sensitivity, excessive activation may paradoxically lead to abnormal fat deposition, and reduced expression is associated with elevated cardiovascular risk. LPL is intimately linked to the pathophysiology of atherosclerosis, obesity, and type 2 diabetes, with specific polymorphisms such as S447X influencing individual susceptibility to cardiovascular disease. Beyond its canonical role in lipid metabolism, LPL is implicated in inflammatory responses and macrophage lipid handling, and it may modulate tumor microenvironment dynamics by regulating the availability of fatty acids essential for cancer cell proliferation.

Loading comments...